Bicycle Therapeutics (FRA:50BA) Tariff Resilience Score: 9/10 (As of Jul. 05, 2026)


FRA:50BA Bicycle Therapeutics PLC FRA:50BA
56 GF Score
Price €3.64
GF Value €12.28
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bicycle Therapeutics Tariff Resilience Score?

Bicycle Therapeutics FRA:50BA +1.11% 56 Tariff Resilience Score is 9 as of Jul. 05, 2026. GuruFocus rates FRA:50BA with a GF Score™ of 56/100 and a GF Value™ of €12.28 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,369 Biotechnology companies, Bicycle Therapeutics ranks better than 99.93% on this metric.

Bicycle Therapeutics has the Tariff Resilience Score of 9, which implies that the company might have Highly Resilient.

Bicycle Therapeutics has Bicycle Therapeutics PLC, a biotech firm, has minimal direct exposure to tariffs. Its focus on R&D and intellectual property provides resilience. The company can source materials from multiple regions, and its industry benefits from certain tariff exemptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Bicycle Therapeutics might have Highly Resilient.

Bicycle Therapeutics  (FRA:50BA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Bicycle Therapeutics Tariff Resilience Score Related Terms

FRA:50BA vs IFRX, ELDN, ZNTL: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Bicycle Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicycle Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Bicycle Therapeutics's Tariff Resilience Score falls into.


FRA:50BA
56GF Score
Bicycle Therapeutics PLC FRA:50BA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 9 mean?
Bicycle Therapeutics (FRA:50BA) has a Tariff Resilience Score of 9 as of Jul. 05, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Bicycle Therapeutics ranks #1 out of 1369 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Bicycle Therapeutics' Tariff Resilience Score too high?
Bicycle Therapeutics' current Tariff Resilience Score is 9. The Biotechnology industry median Tariff Resilience Score is 4.00. Bicycle Therapeutics' value of 9 is 125% above this industry median. Based on the distribution chart, Bicycle Therapeutics ranks #1 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bicycle Therapeutics has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bicycle Therapeutics' Tariff Resilience Score compare to IFRX and ELDN?
According to the Biotechnology industry distribution chart, Bicycle Therapeutics ranks #1 out of 1369 companies for Tariff Resilience Score. This places Bicycle Therapeutics in the top 0% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Bicycle Therapeutics' value of 9 is 125% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bicycle Therapeutics's current Tariff Resilience Score of 9 is 125% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bicycle Therapeutics's current Tariff Resilience Score is 9. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicycle Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bicycle Therapeutics (FRA:50BA) is currently considered Possible Value Trap. The stock's GF Value™ is €12.28, compared to a current price of €3.64 — trading 70.4% below its estimated fair value. The current Tariff Resilience Score is 9 and 125% above the Biotechnology industry median of 4.00. Bicycle Therapeutics' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Bicycle Therapeutics (FRA:50BA), the current Tariff Resilience Score is 9 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bicycle Therapeutics (FRA:50BA) Overvalued in 2026?

Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued. The current stock price of €3.64 is trading 70.4% below its estimated GF Value™ of €12.28. GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:50BA:

  • Tariff Resilience Score: 9
  • GF Value™: €12.28 vs. price of €3.64 (70.4% below fair value)
  • GF Score™: 56/100 with 5 warning signs
  • Industry Position: 125% above the Biotechnology median (#1 of 1369)

No single metric tells the full story. See the FRA:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bicycle Therapeutics Business Description

Other Exchanges BCYC:USA50BA:Germany
Address Granta Park, Great Abington, Blocks A and B, Portway Building, Cambridge, GBR, CB21 6GS
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
56GF Score

Get the complete analysis for FRA:50BA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.64
Price
€12.28
GF Value